Incyte, CMS Partner to Develop Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia
Incyte and China Medical System Holdings Limited (CMS) have entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor, in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria in Mainland China, Hong Kong, Macao, Taiwan Region and […]